Positive Data of T-Cell-Therapy


Hørsholm - The Danish biotech company T-cellic A/S demonstrated that their specific T-cells can act as carriers of compounds in the localization and treatment of cancer tumours and metastases, when highly statistically significant early data was presented at the ASCO meeting. “We have been able to locate tumours with a diameter of less than 10 mm, using the combined PET/MR imaging technology in our mouse melanoma model. This indicates that our pre-clinical proof of concept with T-cell-guided Boron Neutron Capture Therapy using our novel proprietary nano-pharmaceutical is within reach,” says Jan Trøst Jørgensen, VP of Research & Development of T-cellic. T-cells labeled with an imaging agent have been adoptively transferred to mice of a well-established mouse model bearing implanted melanoma tumours. A subsequent image analysis of PET/MR scans demonstrated the T-cell migration to the tumour sites. Results showed a clear homing of the transferred cells to the tumours. T-cellic's research partners at Århus University concluded that these specific, migrating T-cells could be employed in a new form of therapy as carriers of toxic substances to tumours, since these studies show that tumour-specific T-cells home to subcutaneous tumours in substantial numbers.



Bagsvaerd/Bangalore – Danish Novozymes A/S has begun a new collaboration with Indian Sea6 Energy. The companies will jointly develop enzymes to convert seaweed-based carbohydrates to sugar, which can then be fermented to produce...



Prague/Turku/Copenhagen – Danish pharmaceutical company H. Lundbeck A/S yesterday unveiled clinical data on its potential blockbuster drug nalmefene at the 2012 European Congress of Psychiatry clinical in Prague. While Lundbeck...



Copenhagen – With the in vitro proof of concept for an undisclosed antibody target, Genmab A/S has reached the second milestone in its collaboration with H. Lundbeck A/S. Genmab will now receive a €1m payment. Under the...



Copenhagen/Bangalore – Biofuels need reliable sources of biomass. Novozymes now looks to the ocean to secure biomass. The Danish enzyme specialist announced an exploratory research agreement with Sea6 Energy from India. The...



Copenhagen – Hellsinn Healthcare has successfully completed a phase Ib trial in Europe with Zealand Pharma’s GLP-2 (glucagone-like peptide 2) peptide antagonist Elsiglutide (ZP1846). The completion of the study, which was...



Copenhagen - An alliance of giants will take a thorough look into biofuels for the maritime sector. The leading enzyme producer Novozymes will team up with parts of the Danish shipping industry, including the world’s largest...



Copenhagen/Paris – Danish biopharma­ceuticals company Zealand Pharma A/S has received some positive news. Ever since French partner Sanofi Aventis submitted a marketing authorisation application for Lyxumia (lixisenatide) in...



Copenhagen/Paris - The cooperation between Danish biopharmaceutical company Zealand Pharma and French drugmaker Sanofi has borne its first fruit. Sanofi has submitted a marketing authorisation application for Lyxumia...



Copenhagen/Ingelheim – Danish HTS expert Nuevolution A/S has signed a license agreement with drugmaker Boeh­ringer Ingelheim (BI). The German pharma company will use Nuevolution’s proprietary Chemetics drug discovery technology...



Bagsværd - Novo Nordisk is investing around €134m in a new corporate centre in the Copenhagen suburb Bagsværd. The new office premises will concentrate the top management and 1,100 administrative employees which are currently...

Displaying results 1 to 10 out of 194

1-10 Next >

© 2007-2015 BIOCOM


All Events


Product of the week


Current issue

All issues